Literature DB >> 31548813

18 F-Fluorodeoxyglucose positron-emission tomography for the investigation of malignancy in patients with suspected paraneoplastic neurologic syndromes and negative or indeterminate conventional imaging: a retrospective analysis of the Ontario PET Access Program, with systematic review and meta-analysis.

C Harlos1, U Metser2, R Poon3, P MacCrostie4, W Mason5.   

Abstract

Objective: Paraneoplastic neurologic syndrome (pns) is a rare condition indirectly caused by an underlying malignancy. In many cases, the malignancy is occult at the time of the pns diagnosis, and the optimal diagnostic modality to detect the underlying tumour is unclear. In the present study, we aimed to assess the utility of 18F-fluorodeoxyglucose positron-emission tomography (fdg-pet) or pet integrated with computed tomography (pet/ct) in the investigation of these patients.
Methods: We retrospectively analyzed data from the PET Access Program (pap) database in the province of Ontario to identify patients who underwent fdg-pet/ct imaging as part of a workup for pns. In all patients, prior conventional imaging was negative or indeterminate. To determine the diagnostic accuracy of fdg-pet/ct, data about demographics, presenting symptoms, and biochemical and radiologic workup, including fdg-pet/ct imaging results, were compared with data collected by the Ontario Cancer Registry (ocr). A systematic review of the literature and meta-analysis using our study inclusion criteria were performed for studies of fdg-pet accuracy.
Results: Of 29 patients identified in the pap database, 9 had fdg-pet/ct results suspicious for malignancy. When correlated with data from the ocr, 5 fdg-pet/ct results were informative, resulting in a detection rate of 17%. Local sensitivity and specificity were 0.83 and 0.83 respectively. Two studies meeting our criteria were identified in the literature. The pooled sensitivity and specificity from the literature and local data were 0.88 and 0.90 respectively. Conclusions: When investigating for underlying malignancy in patients with suspected pns and negative conventional imaging, pet has high sensitivity and specificity.

Entities:  

Keywords:  Paraneoplastic neurologic syndrome; malignancy; positron-emission tomography; sensitivity; specificity

Year:  2019        PMID: 31548813      PMCID: PMC6726279          DOI: 10.3747/co.26.4583

Source DB:  PubMed          Journal:  Curr Oncol        ISSN: 1198-0052            Impact factor:   3.677


  16 in total

Review 1.  Paraneoplastic syndromes involving the nervous system.

Authors:  Robert B Darnell; Jerome B Posner
Journal:  N Engl J Med       Date:  2003-10-16       Impact factor: 91.245

2.  Exploring sources of heterogeneity in systematic reviews of diagnostic tests.

Authors:  Jeroen G Lijmer; Patrick M M Bossuyt; Siem H Heisterkamp
Journal:  Stat Med       Date:  2002-06-15       Impact factor: 2.373

Review 3.  Paraneoplastic syndromes of the CNS.

Authors:  Josep Dalmau; Myrna R Rosenfeld
Journal:  Lancet Neurol       Date:  2008-04       Impact factor: 44.182

Review 4.  Paraneoplastic neurologic syndromes: pathogenesis and physiopathology.

Authors:  J Dalmau; H S Gultekin; J B Posner
Journal:  Brain Pathol       Date:  1999-04       Impact factor: 6.508

5.  Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations.

Authors:  L E Moses; D Shapiro; B Littenberg
Journal:  Stat Med       Date:  1993-07-30       Impact factor: 2.373

6.  Screening for tumours in paraneoplastic syndromes: report of an EFNS task force.

Authors:  M J Titulaer; R Soffietti; J Dalmau; N E Gilhus; B Giometto; F Graus; W Grisold; J Honnorat; P A E Sillevis Smitt; R Tanasescu; C A Vedeler; R Voltz; J J G M Verschuuren
Journal:  Eur J Neurol       Date:  2010-09-29       Impact factor: 6.089

7.  Recommended diagnostic criteria for paraneoplastic neurological syndromes.

Authors:  F Graus; J Y Delattre; J C Antoine; J Dalmau; B Giometto; W Grisold; J Honnorat; P Sillevis Smitt; Ch Vedeler; J J G M Verschuuren; A Vincent; R Voltz
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-08       Impact factor: 10.154

8.  FDG-PET improves tumour detection in patients with paraneoplastic neurological syndromes.

Authors:  S Younes-Mhenni; M F Janier; L Cinotti; J C Antoine; F Tronc; V Cottin; P J Ternamian; P Trouillas; J Honnorat
Journal:  Brain       Date:  2004-09-10       Impact factor: 13.501

9.  Integrated FDG PET/CT: Utility and Applications in Clinical Oncology.

Authors:  Inmaculada Pinilla; Beatriz Rodríguez-Vigil; Nieves Gómez-León
Journal:  Clin Med Oncol       Date:  2008-09-19

10.  FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0.

Authors:  Ronald Boellaard; Roberto Delgado-Bolton; Wim J G Oyen; Francesco Giammarile; Klaus Tatsch; Wolfgang Eschner; Fred J Verzijlbergen; Sally F Barrington; Lucy C Pike; Wolfgang A Weber; Sigrid Stroobants; Dominique Delbeke; Kevin J Donohoe; Scott Holbrook; Michael M Graham; Giorgio Testanera; Otto S Hoekstra; Josee Zijlstra; Eric Visser; Corneline J Hoekstra; Jan Pruim; Antoon Willemsen; Bertjan Arends; Jörg Kotzerke; Andreas Bockisch; Thomas Beyer; Arturo Chiti; Bernd J Krause
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-12-02       Impact factor: 9.236

View more
  1 in total

1.  Additional Value of [18F]FDG PET/CT in Detection of Suspected Malignancy in Patients with Paraneoplastic Neurological Syndromes Having Negative Results of Conventional Radiological Imaging.

Authors:  Marta Opalińska; Anna Sowa-Staszczak; Kamil Wężyk; Jeremiasz Jagiełła; Agnieszka Słowik; Alicja Hubalewska-Dydejczyk
Journal:  J Clin Med       Date:  2022-03-11       Impact factor: 4.241

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.